| 7.055 0.1 (1.44%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.06  |
1-year : | 16.35 |
| Resists | First : | 11.18 |
Second : | 14 |
| Pivot price | 8.8 |
|||
| Supports | First : | 6.63 |
Second : | 5.52 |
| MAs | MA(5) : | 8.01 |
MA(20) : | 9.09 |
| MA(100) : | 14.17 |
MA(250) : | 16.49 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 15 |
D(3) : | 22.4 |
| RSI | RSI(14): 33.6  |
|||
| 52-week | High : | 30.6 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MCRB ] has closed above bottom band by 5.1%. Bollinger Bands are 34.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.26 - 7.3 | 7.3 - 7.35 |
| Low: | 6.53 - 6.59 | 6.59 - 6.64 |
| Close: | 6.96 - 7.06 | 7.06 - 7.14 |
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Thu, 08 May 2025
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Thu, 08 May 2025
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
Thu, 08 May 2025
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Thu, 08 May 2025
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks
Wed, 07 May 2025
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks
Wed, 07 May 2025
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 13 (%) |
| Held by Institutions | 36.2 (%) |
| Shares Short | 763 (K) |
| Shares Short P.Month | 836 (K) |
| EPS | -16.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.67 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -149 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -0.44 |
| PEG Ratio | 0 |
| Price to Book value | 4.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|